Epsilogen

A London antibody company, spun out of King's College London, developing IgE antibodies as a new way to treat cancer.

About Epsilogen

Epsilogen develops IgE antibodies to treat cancer. IgE is best known for its role in allergy and for defending the body against parasites, and Epsilogen believes that power can be turned against solid tumours. Its lead, MOv18 IgE, targets ovarian cancer and was the first IgE antibody medicine tested in people. It is also building a combined IgEG platform.

We did not find a mission statement. Chief executive Dr Tim Wilson has said IgE antibodies could become an entirely new treatment type for people with cancer.

Epsilogen is a spin-out of King's College London and began operating in 2017. Its announcements are datelined London, and its first trial was run with Guy's and St Thomas' NHS Foundation Trust. We did not find an office address.

Little is public about its culture or team size. We found no 2026 news, so treat its current status as to be confirmed (latest sourced activity: 2024).

We found no sourced internship, apprenticeship or graduate scheme. If you are interested, look at its own website and at King's College London research routes.

What they do

• {'desc': 'Developing antibody medicines using the IgE class.', 'title': 'IgE antibody research'}
• {'desc': 'Lead candidate for ovarian cancer.', 'title': 'MOv18 IgE'}
• {'desc': 'Antibodies combining IgE and IgG features.', 'title': 'IgEG platform'}

Key facts

• Spin-out of King's College London; started operating 2017
• MOv18 IgE was the first therapeutic IgE antibody tested in the clinic
• Phase I trial run with Guy's and St Thomas' NHS Foundation Trust
• CEO: Dr Tim Wilson

Website: www.epsilogen.com